Diabetic retinopathy

December 31, 2017

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing α-linoleic acid, Epicatechin and Matrine (LAEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 1/January/2018, 5.23 am

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing α-linoleic acid, Epicatechin and Matrine (LAEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 1/January/2018, 5.23 am https://genomediscovery.org/wp-content/uploads/2017/12/LAEM-inhibits-EPHX2.sEH1-expression-decreases-1920-dihydroxydocosapentaenoic-acid-DHDP-levels-and-suppresses-Diab.jpg1_.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/LAEM-inhibits-EPHX2.sEH1-expression-decreases-1920-dihydroxydocosapentaenoic-acid-DHDP-levels-and-suppresses-Diab.jpg1_.jpg2_.jpg December 31, 2017 January 1, 2018

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

December 29, 2017

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Nordihydroguaiaretic acid (NDGA), Epicatechin and Matrine (NDGAEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 29/December/2017, 11.22 pm

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Nordihydroguaiaretic acid (NDGA), Epicatechin and Matrine (NDGAEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 29/December/2017, 11.22 pm https://genomediscovery.org/wp-content/uploads/2017/12/NDGAEM-inhibits-diabetic-retinopathy.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/NDGAEM-inhibits-diabetic-retinopathy.jpg2_.jpg December 29, 2017 December 29, 2017

December 24, 2017

Combinatorial therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing 14, 15, Epoxyeicosatrienoic acids (14, 15 EETs), Epicatechin, and Matrine (14, 15, EETEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 25/December/2017, 1.56 am

Combinatorial therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing 14, 15, Epoxyeicosatrienoic acids (14, 15 EETs), Epicatechin, and Matrine (14, 15, EETEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 25/December/2017, 1.56 am https://genomediscovery.org/wp-content/uploads/2017/12/A-pharmaceutical-mixture-encompassing-14-15-Epoxyeicosatrienoic-acid-epicatechin-and-matrine-inhibits-diabetic-retinopathy.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/A-pharmaceutical-mixture-encompassing-14-15-Epoxyeicosatrienoic-acid-epicatechin-and-matrine-inhibits-diabetic-retinopathy.jpg December 24, 2017 December 25, 2017

December 23, 2017

Molecular therapy for Diabetic retinopathy: Dimethyl Fumerate (DMF) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 24/December/2017, 1.10 am

Molecular therapy for Diabetic retinopathy: Dimethyl Fumerate (DMF) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 24/December/2017, 1.10 am https://genomediscovery.org/wp-content/uploads/2017/12/Dimethyl-Fumerate-inhibits-EPHX2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/Dimethyl-Fumerate-inhibits-EPHX2.jpg December 23, 2017 December 23, 2017

December 16, 2017

Natural product-based therapy for Diabetic retinopathy: Notoginsenoside R1, isolated from Panax Notoginseng, inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 16/December/2017, 11.38 pm

Natural product-based therapy for Diabetic retinopathy: Notoginsenoside R1, isolated from Panax Notoginseng, inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 16/December/2017, 11.38 pm https://genomediscovery.org/wp-content/uploads/2017/12/Notoginsenoside-R1-inhibits-sEH1-expression-decreases-1920-dihydroxydocosapentaenoic-acid-level-and-attenuates-the-development-of-diabetic-retinop.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/Notoginsenoside-R1-inhibits-sEH1-expression-decreases-1920-dihydroxydocosapentaenoic-acid-level-and-attenuates-the-development-of-diabetic-retinop.jpg December 16, 2017 December 16, 2017

December 12, 2017

Vitamin-based therapy for Diabetic retinopathy: Pyridoxamine (PM), a form of Vitamin B6, inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 13/December/2017, 1.07 am

Vitamin-based therapy for Diabetic retinopathy: Pyridoxamine (PM), a form of Vitamin B6, inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 13/December/2017, 1.07 am https://genomediscovery.org/wp-content/uploads/2017/12/Pyridoxamine-PM.Vitamin-B6-inhibits-diabetic-retinophathy-through-down-regulation-of-EPHX2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2017/12/Pyridoxamine-PM.Vitamin-B6-inhibits-diabetic-retinophathy-through-down-regulation-of-EPHX2.jpg December 12, 2017 December 13, 2017

Popular Post